Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when NHS England’s Clinical Priorities Advisory Group will consider Arikayce liposomal as a treatment for patients with non-tuberculosis mycobacteria.

A policy proposal for Arikayce Liposomal, also known as Amikacin, is being considered by NHS England and is progressing through its methods process. The policy proposal is currently undergoing stakeholder testing and a date for consideration at the Priorities Advisory Group has not yet been determined.